These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32034504)

  • 1. Cardiovascular Risk Reduction by Pharmacists at the Workplace.
    Macaulay TE; Schaidle S; Wayne N
    Curr Cardiol Rep; 2020 Feb; 22(3):15. PubMed ID: 32034504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Risk Reduction in the Workplace With CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site).
    Gobis B; Kapanen AI; Reardon J; Min J; Li KH; Lynd LD; Zed PJ
    Ann Pharmacother; 2019 Jun; 53(6):574-580. PubMed ID: 30638031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk and Treatment in Cardiovascular Disease (PAART CVD) pilot study.
    Mc Namara KP; George J; O'Reilly SL; Jackson SL; Peterson GM; Howarth H; Bailey MJ; Duncan G; Trinder P; Morabito E; Finch J; Bunker S; Janus E; Emery J; Dunbar JA
    BMC Health Serv Res; 2010 Sep; 10():264. PubMed ID: 20819236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease.
    Altowaijri A; Phillips CJ; Fitzsimmons D
    J Manag Care Pharm; 2013 Jun; 19(5):408-16. PubMed ID: 23697478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacist-led cardiovascular risk prevention in Western Canada: a qualitative study.
    Kapanen AI; Conklin AI; Gobis B; Leung L; Yuen J; Zed PJ
    Int J Pharm Pract; 2021 Feb; 29(1):45-54. PubMed ID: 32779329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study evaluating multiple risk factor interventions by community pharmacists to prevent cardiovascular disease: the PAART CVD pilot project.
    McNamara KP; O'Reilly SL; Dunbar JA; Bailey MJ; George J; Peterson GM; Jackson SL; Janus ED; Bunker S; Duncan G; Howarth H
    Ann Pharmacother; 2012 Feb; 46(2):183-91. PubMed ID: 22318928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting Goals to Reduce Cardiovascular Risk: A Retrospective Chart Review of a Pharmacist-Led Initiative in the Workplace.
    Klaassen AE; Kapanen AI; Zed PJ; Conklin AI
    Int J Environ Res Public Health; 2023 Jan; 20(1):. PubMed ID: 36613168
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials.
    Santschi V; Chiolero A; Burnand B; Colosimo AL; Paradis G
    Arch Intern Med; 2011 Sep; 171(16):1441-53. PubMed ID: 21911628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community pharmacist led, employer-based wellness services: A pilot study.
    Gatwood J; Hanley R; Moore JS; Hohmeier K
    Res Social Adm Pharm; 2019 May; 15(5):615-618. PubMed ID: 29909933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.
    Wittayanukorn S; Westrick SC; Hansen RA; Billor N; Braxton-Lloyd K; Fox BI; Garza KB
    J Manag Care Pharm; 2013 Jun; 19(5):385-95. PubMed ID: 23697476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the Clinical Pharmacist in a Preventive Cardiology Practice.
    Warden BA; Shapiro MD; Fazio S
    Ann Pharmacother; 2019 Dec; 53(12):1214-1219. PubMed ID: 31342786
    [No Abstract]   [Full Text] [Related]  

  • 13. Promoting health and wellness in the workplace: a unique opportunity to establish primary and extended secondary cardiovascular risk reduction programs.
    Arena R; Guazzi M; Briggs PD; Cahalin LP; Myers J; Kaminsky LA; Forman DE; Cipriano G; Borghi-Silva A; Babu AS; Lavie CJ
    Mayo Clin Proc; 2013 Jun; 88(6):605-17. PubMed ID: 23726400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Workplace wellness recognition for optimizing workplace health: a presidential advisory from the American Heart Association.
    Fonarow GC; Calitz C; Arena R; Baase C; Isaac FW; Lloyd-Jones D; Peterson ED; Pronk N; Sanchez E; Terry PE; Volpp KG; Antman EM;
    Circulation; 2015 May; 131(20):e480-97. PubMed ID: 25869199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Workplace-based cardiovascular risk management by community pharmacists: impact on blood pressure, lipid levels, and weight.
    John EJ; Vavra T; Farris K; Currie J; Doucette W; Button-Neumann B; Osterhaus M; Kumbera P; Halterman T; Bullock T
    Pharmacotherapy; 2006 Oct; 26(10):1511-7. PubMed ID: 16999661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of community pharmacists' preparedness for the provision of cardiovascular disease risk assessment and management services: A study with simulated patients.
    Zolezzi M; Abdallah O; Kheir N; Abdelsalam AG
    Res Social Adm Pharm; 2019 Mar; 15(3):252-259. PubMed ID: 29753643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster-Randomized Trial to Evaluate a Centralized Clinical Pharmacy Service in Private Family Medicine Offices.
    Carter BL; Levy B; Gryzlak B; Xu Y; Chrischilles E; Dawson J; Vander Weg M; Christensen A; James P; Polgreen L
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004188. PubMed ID: 29884657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Task shifting of cardiovascular risk assessment and communication by nurses for primary and secondary prevention of cardiovascular diseases in a tertiary health care setting of Northern India.
    Kavita ; Thakur JS; Vijayvergiya R; Ghai S
    BMC Health Serv Res; 2020 Jan; 20(1):10. PubMed ID: 31900134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of interventions ≥ 6 months by pharmacists on adherence to medicines in cardiovascular disease: Characteristics of what works and what doesn't.
    Doggrell SA
    Res Social Adm Pharm; 2019 Feb; 15(2):119-129. PubMed ID: 29656935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pharmacist in cardiovascular disease-related health promotion and in hypertension and dyslipidemia management: a cross-sectional study in the State of Qatar.
    El Hajj MS; Mahfoud ZR; Al Suwaidi J; Alkhiyami D; Alasmar AR
    J Eval Clin Pract; 2016 Jun; 22(3):329-40. PubMed ID: 26552842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.